OR WAIT null SECS
Datwyler is channelling more than CHF 100 million into building a new plant in the US state of Delaware, which will be used to manufacture elastomer components for injectable drug-delivery systems.
Datwyler has announced plans to further expand its production capacity for elastomer components used in injectable drug-delivery systems. The company is investing more than CHF 100 million to build a new plant in the US state of Delaware for the manufacture of high-quality elastomer components.
Construction work is expected to begin before the end of 2016, with production scheduled to start in the first half of 2018. Once up and running, Datwyler’s new, highly automated plant in the US will provide jobs for approximately 120 employees.
Datwyler has been operating its own plant in the US since 1981. The new production site in Delaware is to be designed, built, and run in accordance with Datwyler’s latest “first-line” standards. The approach is based on a manufacturing concept for high-quality elastomer components using ultra-modern clean room technology, automated production cells, fully automated camera inspection, and a unique washing process, all of which complies with stringent quality standards of the European and US regulatory authorities and is certified to ISO 15378.